Annegien Broeks

42.1k total citations · 3 hit papers
85 papers, 3.9k citations indexed

About

Annegien Broeks is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Annegien Broeks has authored 85 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 27 papers in Cancer Research and 21 papers in Molecular Biology. Recurrent topics in Annegien Broeks's work include Cancer Immunotherapy and Biomarkers (32 papers), Cancer Genomics and Diagnostics (14 papers) and Breast Cancer Treatment Studies (11 papers). Annegien Broeks is often cited by papers focused on Cancer Immunotherapy and Biomarkers (32 papers), Cancer Genomics and Diagnostics (14 papers) and Breast Cancer Treatment Studies (11 papers). Annegien Broeks collaborates with scholars based in Netherlands, United States and Australia. Annegien Broeks's co-authors include Ronald H.A. Plasterk, Flora E. van Leeuwen, Nicola S. Russell, Christian U. Blank, Joyce B. J. van Meurs, Ingrid Hofland, J. T. M. Groenen, Laura J. van’t Veer, Lodewyk F.A. Wessels and Ton N. Schumacher and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Annegien Broeks

80 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

2017 504 citations Ingrid Hofland, Annegien Broeks et al. profile →
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

2021 195 citations Annegien Broeks, Joyce Sanders et al. profile →
A pan-cancer analysis of the microbiome in metastatic cancer

2024 94 citations Joleen J.H. Traets, Ingrid Hofland et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annegien Broeks Netherlands	29	1.7k	1.4k	742	598	570	85	3.9k
Sam Behjati United Kingdom	24	1.7k 1.0×	2.1k 1.5×	825 1.1×	1.3k 2.2×	306 0.5×	62	4.4k
Raj Chari United States	36	603 0.4×	3.2k 2.4×	816 1.1×	348 0.6×	274 0.5×	98	4.2k
Edward Fox United States	32	802 0.5×	2.1k 1.6×	1.3k 1.7×	537 0.9×	748 1.3×	94	4.1k
Judith M. Boer Netherlands	36	650 0.4×	2.7k 2.0×	713 1.0×	658 1.1×	367 0.6×	94	4.7k
Carl W. Miller United States	41	1.7k 1.0×	2.8k 2.1×	665 0.9×	513 0.9×	430 0.8×	90	4.7k
Toshiya Inaba Japan	37	799 0.5×	2.6k 1.9×	492 0.7×	653 1.1×	219 0.4×	124	4.6k
Sachiko Kajigaya United States	46	723 0.4×	2.5k 1.9×	623 0.8×	1.4k 2.4×	155 0.3×	157	6.6k
Bastiaan B.J. Tops Netherlands	28	521 0.3×	2.7k 2.0×	2.1k 2.8×	255 0.4×	361 0.6×	70	4.3k
Daniel J. Donoghue United States	44	1.1k 0.7×	4.2k 3.1×	391 0.5×	384 0.6×	180 0.3×	127	5.6k
Hesed Padilla‐Nash United States	28	737 0.4×	2.1k 1.6×	703 0.9×	158 0.3×	235 0.4×	56	3.9k

Countries citing papers authored by Annegien Broeks

Since Specialization

Citations

This map shows the geographic impact of Annegien Broeks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annegien Broeks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annegien Broeks more than expected).

Fields of papers citing papers by Annegien Broeks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annegien Broeks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annegien Broeks. The network helps show where Annegien Broeks may publish in the future.

Co-authorship network of co-authors of Annegien Broeks

This figure shows the co-authorship network connecting the top 25 collaborators of Annegien Broeks. A scholar is included among the top collaborators of Annegien Broeks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annegien Broeks. Annegien Broeks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dijk, Nick van, Daniël J. Vis, Bram van den Broek, et al.. (2025). Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial. European Journal of Cancer. 229. 115731–115731.

Monkhorst, Kim, Gabe S. Sonke, Annegien Broeks, et al.. (2025). Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastases. The Breast. 85. 104674–104674.

Vos, Joris L., Joleen J.H. Traets, Xiaohang Qiao, et al.. (2024). Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. JCI Insight. 9(21). 5 indexed citations

Gil-Jimenez, Alberto, Nick van Dijk, Joris L. Vos, et al.. (2024). Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors. Nature Communications. 15(1). 2538–2538. 10 indexed citations

Zande, Kim van der, Paul Hamberg, Annegien Broeks, et al.. (2024). Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy. Clinical Genitourinary Cancer. 22(2). 445–453.e1. 2 indexed citations

Wilpe, Sandra van, Iris M. Seignette, Alberto Gil-Jimenez, et al.. (2024). Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment. Clinical Cancer Research. 30(18). 4227–4239. 3 indexed citations

Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660. 2 indexed citations

Steenbruggen, Tessa G., Denise M. Wolf, Bram Thijssen, et al.. (2023). Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort. JCO Precision Oncology. 7(7). e2200670–e2200670. 1 indexed citations

Hoeijmakers, Lianne, Marta López‐Yurda, Lindsay G. Grijpink-Ongering, et al.. (2023). 1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial. Annals of Oncology. 34. S670–S670. 1 indexed citations

10.

Smid, Marcel, Marjanka K. Schmidt, Wendy J. C. Prager‐van der Smissen, et al.. (2023). Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile. Breast Cancer Research. 25(1). 53–53. 5 indexed citations

11.

Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2022). PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical Cancer Research. 28(22). 4893–4906. 26 indexed citations

12.

Gil-Jimenez, Alberto, Alberto Contreras‐Sanz, Daniël J. Vis, et al.. (2022). Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. European Urology. 83(4). 313–317. 26 indexed citations

13.

Koemans, Willem J., Jolanda M. van Dieren, José G. van den Berg, et al.. (2021). High CD8 ⁺ tumour‐infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy. Histopathology. 79(2). 238–251. 7 indexed citations

14.

Cimino‐Mathews, Ashley, Yoni Lubeck, Mark Opdam, et al.. (2020). Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. European Journal of Cancer. 127. 240–250. 18 indexed citations

15.

Scanu, Tiziana, Robbert M. Spaapen, Chandra Bhan Pratap, et al.. (2015). Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma. Cell Host & Microbe. 17(6). 763–774. 190 indexed citations

16.

Broek, Alexandra J. van den, Annegien Broeks, Hugo M. Horlings, et al.. (2011). Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. Breast Cancer Research and Treatment. 130(2). 599–608. 7 indexed citations

17.

Broeks, Annegien, Linde M. Braaf, Angelina Huseinovic, et al.. (2007). Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Research. 9(2). R26–R26. 62 indexed citations

18.

Szabo, Csilla I., Mieke Schutte, Annegien Broeks, et al.. (2004). Are ATM Mutations 7271T→G and IVS10-6T→G Really High-Risk Breast Cancer-Susceptibility Alleles?. Cancer Research. 64(3). 840–843. 43 indexed citations

19.

Broeks, Annegien, Jos Urbanus, Arno Floore, et al.. (2000). ATM-Heterozygous Germline Mutations Contribute to Breast Cancer–Susceptibility. The American Journal of Human Genetics. 66(2). 494–500. 186 indexed citations

20.

Broeks, Annegien, Bernard Gerrard, Rando Allikmets, Michael Dean, & Ronald H.A. Plasterk. (1996). Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans.. The EMBO Journal. 15(22). 6132–6143. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact